Fluoropolymer‐Mediated Delivery of a Dual TSHR/IGF1R‐Targeting CRISPR‐Cas9 System for Localized Therapy in Thyroid‐Associated Ophthalmopathy
Advanced Materials · 2026-02 · 38 (11)
DOI: 10.1002/adma.202511078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 04.01.2026. Verfasst von Mingsu Shi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Receptor, IGF Type 1, Graves Ophthalmopathy, CRISPR-Cas Systems, Receptors, Thyrotropin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Clinical Scientist Foundation of Fudan University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Thyroid‐associated ophthalmopathy (TAO), a vision‐threatening and disfiguring autoimmune orbital disorder, remains a therapeutic challenge due to the lack of therapies with orbital specificity, sustained efficacy, and minimal side effects. Herein, we present G4F7‐CRISPR, a fluoropolymer‐based CRISPR‐Cas9 delivery platform engineered for localized and efficient disruption of thyroid‐stimulating hormone receptor ( TSHR ) and insulin‐like growth factor 1 receptor ( IGF1R ), two key mediators of TAO pathogenesis. G4F7‐CRISPR achieved high insertion/deletion frequencies in primary orbital fibroblasts ( Tshr : 37.2%; Igf1r : 42.8%) and mature adipocytes ( Tshr : 22.4%; Igf1r : 24.3%), and maintained robust editing efficiency in orbital adipose tissue of TAO mouse models ( Tshr : 30.7%; Igf1r : 32.4%). In both TAO mouse models and 3D human orbital organoids, dual‐gene editing of Tshr and Igf1r via G4F7‐CRISPR significantly suppressed orbital adipogenesis, inflammation, and fibrosis, demonstrating superior therapeutic efficacy over either single‐gene approaches. Comprehensive off‐target analyses in both TAO mouse models and orbital organoids revealed minimal off‐target activity. Furthermore, G4F7‐CRISPR exhibited excellent short‐ and long‐term ocular and systemic safety in TAO mouse models. Notably, it outperformed teprotumumab—the FDA‐approved therapy for TAO—in both therapeutic efficacy and safety, highlighting its potential clinical advantages. Collectively, these findings highlight the translational promise of G4F7‐CRISPR as a safe, precise, and clinically viable gene therapy for TAO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
- Key laboratory of Myopia and Related Eye Diseases, NHC, Shanghai, China.
- Key laboratory of Myopia and Related Eye Diseases, Chinese Academy of Medical Sciences, Shanghai, China.
- Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, China.
- Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai, China.
- Xiamen Eye Center of Xiamen University, Xiamen, China.
ORCID-Profile: Chen Zhao
Förderung
- Clinical Scientist Foundation of Fudan University
- National Natural Science Foundation of China
Zitieren
APA
Shi, M., Yu, P., Liu, L., Cheng, J., Shao, R., Sun, Y., Lv, J., Li, Y., Zheng, Z., Yu, J., Xu, B., Gan, L., Liang, Y., Zhang, Y., Fang, Y., Shen, W., Huang, J., Zhu, X., Hong, J., …, & Zhao, C. (2026). Fluoropolymer‐Mediated Delivery of a Dual TSHR/IGF1R‐Targeting CRISPR‐Cas9 System for Localized Therapy in Thyroid‐Associated Ophthalmopathy. Advanced Materials, 38(11). https://doi.org/10.1002/adma.202511078
Vancouver
Shi M, Yu P, Liu L, Cheng J, Shao R, Sun Y, et al. Fluoropolymer‐Mediated Delivery of a Dual TSHR/IGF1R‐Targeting CRISPR‐Cas9 System for Localized Therapy in Thyroid‐Associated Ophthalmopathy. Advanced Materials. 2026;38(11). doi:10.1002/adma.202511078
BibTeX
@article{Shi2026,
author = {Shi, Mingsu and Yu, Panting and Liu, Lingyun and Cheng, Jinwei and Shao, Runyi and Sun, Ye and Lv, Jia and Li, Yuhan and Zheng, Zihan and Yu, Jian and Xu, Binbin and Gan, Lu and Liang, Yu and Zhang, Yihan and Fang, Yanxi and Shen, Weiai and Huang, Jinhai and Zhu, Xiangjia and Hong, Jiaxu and Ma, Ruiqi and Wu, Lianqun and Cheng, Yiyun and Zhao, Chen},
title = {Fluoropolymer‐Mediated Delivery of a Dual TSHR/IGF1R‐Targeting CRISPR‐Cas9 System for Localized Therapy in Thyroid‐Associated Ophthalmopathy},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {11},
doi = {10.1002/adma.202511078}
}
EUVIMED